Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (NCT07018453).

Runs
5
Findings
5
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial active not recruiting, primary completion estimated Feb 2026 (current date Apr 2026). No public readout or results found in searches across ClinicalTrials.gov, sponsor sites, or news. Sponsor lists Ph2 SHR-3167 T2D readout expected 2H 2026, confirming no results yet.

Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM
ClinicalTrialsclinicaltrials.gov
ClinicalTrials.gov NCT07018453
Status: Active, not recruiting. Estimated Primary Completion Date: February 2026. No results posted.
Sponsorhengrui.comApr 6, 2026, 12:00 AM
Hengrui 2025 Annual Report
SHR-3167 Insulin T2D Ph2 readout scheduled for 2H 2026 under select Ph1/Ph2 data readouts.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial (NCT07018453) is Phase 2, active not recruiting, primary completion Feb 2026. No results posted on ClinicalTrials.gov or public readouts found. Related Phase 1 data showed glucose-lowering but is not this exact trial.

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:19 PM
Web Searchclinicaltrials.gov
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Current status: Active, Not Recruiting. Estimated primary completion: 2026-02-01. Primary endpoint: Change in HbA1c from baseline at 16 weeks. No results posted.
Web Searchdiabetesjournals.orgJun 20, 2025, 12:00 AM
829-P: Once-Weekly Insulin SHR-3167 in Healthy Subjects and Type 2 Diabetes Mellitus Participants
Phase 1 MAD in basal insulin patients (different comparator glargine, not this trial): HbA1c reduction dose-dependent but no efficacy claim for this specific Phase 2 vs degludec.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
ClinicalTrialsclinicaltrials.govNov 18, 2025, 12:00 AM
Study Details | NCT07018453 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-02; hasResults=false on the latest posted update.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public Phase 2 efficacy readout was found. ClinicalTrials.gov still shows NCT07018453 as Active, not recruiting, and Hengrui materials place SHR-3167 in Phase II pipeline rather than reporting topline results. Without a clear trial-specific readout, outcome cannot be judged positive or negative.

Found Apr 3, 2026, 4:04 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT07018453 | ClinicalTrials.gov
ClinicalTrials.gov identifies NCT07018453 as the SHR-3167 vs insulin degludec Phase 2 study in type 2 diabetes; no public results/readout were located from this record.
Sponsorhengrui.com
Jiangsu Hengrui Pharma Hong Kong prospectus pipeline PDF
Hengrui’s pipeline figure, dated as of April 30, 2025, lists SHR-3167 for diabetes in Phase II, indicating ongoing development rather than a disclosed Phase 2 outcome for this exact trial.
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No exact Phase 2 public readout was found for NCT07018453. The registry mirror still shows this as the ongoing randomized Phase II SHR-3167 vs insulin degludec study, Hengrui materials still place SHR-3167 in Phase II, and the sponsor’s public 2025 ADA disclosure for SHR-3167 was Phase 1 data, not this trial.

Found Apr 1, 2026, 6:48 PMReviewed Apr 1, 2026, 7:04 PM
ClinicalTrialsichgcp.net
NCT07018453 - SHR-3167 and insulin degludec in type 2 diabetes
Registry mirror for NCT07018453 identifies the exact randomized Phase II SHR-3167 vs insulin degludec study and shows only study-record updates, not a results readout.
Sponsorhengrui.comJun 23, 2025, 12:00 AM
2025 ADA | Hengrui disclosed 9 diabetes studies, including SHR-3167
Hengrui’s public ADA 2025 summary for SHR-3167 describes a Phase 1 dose-escalation study in healthy subjects/T2D, not the Phase 2 degludec-comparator trial.
Sponsorhengrui.com
Documents on Display - Hengrui investor materials
Official Hengrui materials still list SHR-3167 under Phase II pipeline status, without any positive or negative trial-specific outcome language for NCT07018453.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.